CAMBRIDGE NUTRITIONAL SCIENCES PLC — Share Issue/Capital Change 2020

Nov 23, 2020

National Storage Mechanism | Additional information

RNS Number : 1672G

Omega Diagnostics Group PLC

23 November 2020

23 November 2020

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 68,478  new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options under the Company's Sharesave scheme by certain option holders.

Application has been made to the London Stock Exchange for the 68,478  new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 27 November 2020.

After Admission, the total number of Ordinary Shares in issue will be 179,864,513 and the total number of voting rights will therefore be 179,864,513. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts: 

Omega Diagnostics Group PLC	Tel: 01259 763 030
Colin King, Chief Executive	www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd	Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)
Walbrook PR Limited	Tel: 020 7933 8780 or [email protected]
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRFEFSUDESSELF